CXC chemokine receptor 4 (CXCR4) blockade in cancer treatment
Journal of Cancer Research and Clinical Oncology · 2023
DOI: 10.1007/s00432-022-04444-w ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Cancer Research and Clinical Oncology, 2023. Verfasst von Shunshun Bao und 14 weiteren Autor:innen. Beteiligte Einrichtung: The First Clinical Medical College, Xuzhou Medical University, 221000, Xuzhou, China. Hauptthemen laut MEDLINE: Receptors, CXCR4, Neoplasms. Die Arbeit wurde bisher 45-mal zitiert (Crossref) und nennt 303 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
CXC chemokine receptor type 4 (CXCR4) is a member of the G protein-coupled receptors (GPCRs) superfamily and is specific for CXC chemokine ligand 12 (CXCL12, also known as SDF-1), which makes CXCL12/CXCR4 axis. CXCR4 interacts with its ligand, triggering downstream signaling pathways that influence cell proliferation chemotaxis, migration, and gene expression. The interaction also regulates physiological processes, including hematopoiesis, organogenesis, and tissue repair. Multiple evidence revealed that CXCL12/CXCR4 axis is implicated in several pathways involved in carcinogenesis and plays a key role in tumor growth, survival, angiogenesis, metastasis, and therapeutic resistance. Several CXCR4-targeting compounds have been discovered and used for preclinical and clinical cancer therapy, most of which have shown promising anti-tumor activity. In this review, we summarized the physiological signaling of the CXCL12/CXCR4 axis and described the role of this axis in tumor progression, and focused on the potential therapeutic options and strategies to block CXCR4.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- The First Clinical Medical College, Xuzhou Medical University, 221000, Xuzhou, China.
- Infectious Diseases and Tropical Medicine Research Center (IDTMRC), Department of Aerospace and Subaquatic Medicine, AJA University of Medicinal Sciences, Tehran, Iran.
- Deanship of Scientific Research, Umm Al-Qura University, 21955, Makkah, Saudi Arabia.
- Zoology Department, Faculty of Science, Mansoura University, 35516, Mansoura, Egypt.
- Department of Physiotherapy, Cihan University-Erbil, Erbil, Kurdistan Region, Iraq.
- An Independent Researcher, National Institute of Technology Durgapur, Durgapur, West Bengal, India.
Zitieren
APA
Bao, S., Darvishi, M., H Amin, A., Al-Haideri, M. T., Patra, I., Kashikova, K., Ahmad, I., Alsaikhan, F., Al-Qaim, Z. H., Al-Gazally, M. E., Kiasari, B. A., Tavakoli-Far, B., Sidikov, A. A., Mustafa, Y. F., & Akhavan-Sigari, R. (2023). CXC chemokine receptor 4 (CXCR4) blockade in cancer treatment. Journal of Cancer Research and Clinical Oncology. https://doi.org/10.1007/s00432-022-04444-w
Vancouver
Bao S, Darvishi M, H Amin A, Al-Haideri MT, Patra I, Kashikova K, et al. CXC chemokine receptor 4 (CXCR4) blockade in cancer treatment. Journal of Cancer Research and Clinical Oncology. 2023. doi:10.1007/s00432-022-04444-w
BibTeX
@article{Bao2023,
author = {Bao, Shunshun and Darvishi, Mohammad and H Amin, Ali and Al-Haideri, Maysoon T and Patra, Indrajit and Kashikova, Khadisha and Ahmad, Irfan and Alsaikhan, Fahad and Al-Qaim, Zahraa Haleem and Al-Gazally, Moaed E and Kiasari, Bahman Abedi and Tavakoli-Far, Bahareh and Sidikov, Akmal A and Mustafa, Yasser Fakri and Akhavan-Sigari, Reza},
title = {CXC chemokine receptor 4 (CXCR4) blockade in cancer treatment},
journal = {Journal of Cancer Research and Clinical Oncology},
year = {2023},
doi = {10.1007/s00432-022-04444-w}
}
EUVIMED